Ipsen S.A. (VIE:IPN)

Market Cap	12.61B +36.1%
Revenue (ttm)	3.93B +9.9%
Net Income	443.50M +28.2%
EPS	5.32 +28.2%
Shares Out	n/a
PE Ratio	28.43
Forward PE	12.22
Dividend	1.40 (0.89%)
Ex-Dividend Date	Jun 4, 2025

Volume	n/a
Average Volume	7
Open	153.90
Previous Close	154.30
Day's Range	153.90 - 153.90
52-Week Range	88.30 - 166.60
Beta	n/a
RSI	51.09
Earnings Date	Apr 16, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i...

• Industry: Pharmaceutical Preparations
• Founded: 1929
• Employees: 5,535
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: IPN

Financial Performance

In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.